Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals for 1.025 billion euros to establish a presence in cardiovascular disease.

Novo Nordisk (NVO) to Buy Cardior to Boost Heart Disease Pipeline

NVIDIA

Novo Nordisk and Nvidia are collaborating on a new computing center. It'll be located in Denmark, and devoted to biomedical research.

Novo Nordisk and Nvidia Just Partnered on AI. Is the Stock a Buy?

Eli Lilly

Viking Therapeutics

Eli Lilly has a big winner with Zepbound plus other growth drivers and a promising late-stage pipeline. Novo Nordisk's Ozempic and Wegovy are huge successes with more great drugs potentially on the way.

Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?

Novo Nordisk (NVO) closed the most recent trading day at $129.05, moving +0.23% from the previous trading session.

Why the Market Dipped But Novo Nordisk (NVO) Gained Today

Novo Nordisk AS (NVO), maker of the weight-loss drug Wegovy, is set to acquire Cardior Pharmaceuticals, a German drug company, in a deal for up to 1.025 billion euros ($1.11 billion).

Novo Nordisk Buys Heart Disease Drug Maker Cardior in $1.11 Billion Deal

Novo Nordisk is one of the leading drugmakers in the world, developing hit medications such as Ozempic. The company is using artificial intelligence (AI) to process larger volumes of data from clinical trials.

Uncovering Hidden Gems: 1 AI-Powered Healthcare Stock Set to Dominate the Market

Novo Nordisk said it plans to seek coverage by Germany's public health insurance scheme for the use of its Wegovy drug to cut the risk of strokes and heart attacks, if the drug's extended indication wins European approval.

Novo ready to seek German insurance coverage of Wegovy for heart use

NEW YORK--(BUSINESS WIRE)--Actylis and Novo Nordisk Pharmatech A/S have entered into an agreement for the distribution of pharmaceutical grade Benzalkonium Chloride (BKC) to the pharmaceutical and medical device markets in Germany, Spain, Portugal, UK and Ireland. By combining Novo Nordisk Pharmatech's leading position as a manufacturer of the highest standards of pharmaceutical grade quaternary ammonium compounds (Quats), with Actylis' expertise and infrastructure in critical raw material dist.

Actylis and Novo Nordisk Pharmatech Announce a Strategic Partnership for the Distribution of Benzalkonium Chloride in Targeted European Countries.

Novo Nordisk, the Danish pharmaceutical whose market cap has swelled due to popular weight loss drugs, on Monday announced it was making an acquisition targeting cardiovascular disease.

Novo Nordisk targets heart disease in $1.1 billion deal

Demand for obesity and diabetes treatments such as Ozempic, Mounjaro, and Wegovy is off the charts. Novo Nordisk and Eli Lilly manufacture the primary medications used to treat obesity care and diabetes.

Novo Nordisk and Eli Lilly May Finally Have Some Real Competition

Denmark's Novo Nordisk on Monday said it has agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros ($1.11 billion) to strengthen its cardiovascular pipeline.

Novo Nordisk to buy Cardior Pharmaceuticals for up to $1.1 bln

Bagsværd, Denmark, and Han n over, Germany, 25 March, 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved.

Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease

Novo Nordisk's Articles of Association 2024 Attachment Articles of Association 21 Mar 2024

Novo Nordisk A/S - Articles of Association 2024

Two of the year's biggest investment themes, artificial intelligence and anti-obesity drugs, are finally meeting up, as Novo Nordisk A/S NYSE: NVO and Nvidia Corp. NASDAQ: NVDA announced a partnership to develop supercomputers.

Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer

Some patients are willing to pay more for GLP-1 weight loss drugs like Wegovy than others — and it's strongly correlated to their annual income.

Here's how much people are willing to spend on weight loss drugs, according to a new survey

Novo Nordisk (NVO) receives a positive opinion from the CHMP for once-weekly basal insulin icodec for the treatment of diabetes in adults.

Novo Nordisk (NVO) Gets Positive CHMP Opinion for Insulin Icodec

Novo Nordisk dominates the obesity and diabetes markets thanks to its long list of hit medications. Wegovy was just approved for an expanded indication, and Novo Nordisk's Amycretin could be its next blockbuster drug.

With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk?

Germany's public health insurance scheme can cover certain patients with a risk of heart disease or strokes to take the weight-loss Wegovy drug, a big boost for Novo Nordisk's efforts to convince governments of its wider medical benefits.

Germany's health insurance could cover Wegovy for strokes, heart conditions, agency says

Amgen

Intellia Therapeutics

When it comes to risk vs. reward in the stock market, the biotech sector has one of the highest potential payoffs.

Hot Stocks: The 3 Best Opportunities for Investing in Biotech

Older adults may now get Medicare coverage for the popular obesity drug Wegovy, so long as they're using it to cut their risk of serious heart problems and not for weight loss alone, according to new guidance from the Centers for Medicare and Medicaid Services.

Medicare allows coverage of Wegovy for heart patients

Novo Nordisk and Eli Lilly stocks edged higher Thursday after Medicare said it could pay for weight-loss drugs for some members.

Medicare Will Cover Weight-Loss Drugs — For Some. Here's What It Means For Novo, Lilly.

Novo Nordisk (NYSE:NVO) is at risk of missing first-quarter consensus estimates, due in part to the slow uptake of its flagship Wegovy drug in the US, Jefferies analysts have warned. As per the bank, sales over the first quarter will likely sit at 59.1 billion Danish Krone, 9% lower than consensus estimates of 64.7 billion.

Novo Nordisk sales face hit on slow US uptake of weight loss drug - analysts

Danish drugmaker Novo Nordisk on Thursday said its once-weekly basal insulin icodec for treatment of diabetes in adults had received a recommendation for marketing authorisation from the European Medicines Agency's human medicines committee.

Novo Nordisk's once-weekly basal insulin icodec recommended for marketing approval in Europe

Bagsværd, Denmark, 21 March 2024 - Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, chair of the Board of Directors communicated: “We are very pleased with the performance in 2023 which was an exceptional year of innovation, growth, value creation and impact for Novo Nordisk.

Resolutions from the Annual General Meeting of Novo Nordisk A/S

Broadcom

eBay

Lowe's

Lyft

Spotify

Toll Brothers

What a difference a Fed meeting can make. Stocks are again ripping higher after the U.S. Federal Reserve signalled that it still expects to deliver three interest rate cuts this year.

News for Novo Nordisk Stock (NVO)